CYC065

Research use only, not for human use.

CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9; demonstrates cytotoxicity both in MM cell lines sensitive as well as resistant to conventional chemotherapy with IC50 of 0.06-2 uM; blocks cells in the G1 phase and inhibits cell growth specifically in CCNE1-overexpressing USCs; significantly reduces tumour growth in xenografts derived from CCNE1-amplified USCs, shows synergistic effect in vitro and in vivo combined with Taselisib .Brain Cancer Phase 1 Clinical

CYC-065;CYC 065

Angiogenesis

CDK

CDK

Cancer

Brain Cancer

1070790-89-4

397.53

C21H31N7O

>98% (HPLC)

DMSO : ≥ 100 mg/mL251.56 mM

CCC(C(C)O)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CN=C(C=C3C)C

(2R,3S)-3-[[6-[(4,6-dimethylpyridin-3-yl)methylamino]-9-propan-2-ylpurin-2-yl]amino]pentan-2-ol

(-20℃)

With Ice Pack

≥ 2 years